Radioactive cocktail targets Hard-to-Treat breast cancer
NCT ID NCT05870579
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new combination of drugs for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. The experimental treatment includes a radioactive drug (lutetium NeoB) that targets cancer cells, plus two standard hormone therapies (ribociclib and fulvestrant). The main goal is to find a safe dose and check for side effects in about 22 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lutetium NeoB (a radioactive drug) combined with ribociclib and fulvestrant
What this could lead to
If successful, this could provide a new treatment option for people with advanced breast cancer that no longer responds to standard hormone therapy.
What could go wrong
This is a very early, small phase 1 trial focused on safety and dosing, so it is not yet known if the combination is effective. There are also risks of side effects from the radioactive drug and the other medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Saint-Cloud, Hauts De Seine, 92210, France
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Gliwice, 44 101, Poland
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
UCLA Jonsson Comp Cancer Center
Los Angeles, California, 90095, United States